Breaking News Instant updates and real-time market news.

AEGN

Aegion

$20.30

-0.47 (-2.26%)

, GRUB

GrubHub

$55.82

-0.27 (-0.48%)

08:12
08/10/17
08/10
08:12
08/10/17
08:12

Canaccord Genuity to hold a conference

37th Annual Growth Conference is being held in Boston on August 9-10 with webcasted company presentations to begin on August 10 at 8 am; not all company presentations may be webcasted. Webcast Link

AEGN

Aegion

$20.30

-0.47 (-2.26%)

GRUB

GrubHub

$55.82

-0.27 (-0.48%)

HIVE

Aerohive

$3.35

-0.05 (-1.47%)

TCMD

Tactile Systems

$32.97

-0.36 (-1.08%)

AST

Asterias

$3.30

-0.15 (-4.35%)

ANGO

AngioDynamics

$16.40

-0.06 (-0.36%)

CAMP

CalAmp

$18.86

-0.12 (-0.63%)

SCYX

SCYNEXIS

$1.63

-0.01 (-0.61%)

VIVO

Meridian Bioscience

$13.60

0.05 (0.37%)

EXAC

Exactech

QTNA

Quantenna Communications

$17.88

-0.13 (-0.72%)

VRML

Vermillion

$1.38

-0.08 (-5.48%)

RVLT

Revolution Lighting

$7.30

-0.03 (-0.41%)

BSQR

Bsquare Corp

$5.05

-0.25 (-4.72%)

PTN

Palatin

$0.40

-0.0226 (-5.41%)

EXA

Exa Corp.

$13.75

-0.21 (-1.50%)

  • 10

    Aug

  • 14

    Aug

  • 15

    Aug

  • 17

    Aug

  • 12

    Sep

  • 08

    Nov

AEGN Aegion
$20.30

-0.47 (-2.26%)

05/17/17
ADAM
05/17/17
NO CHANGE
Target $30
ADAM
Buy
Aegion fundamentals intact despite selloff, says Canaccord
Canaccord analyst Bobby Burleson noted Aegion shares are down roughly 20% since April, but he believes the story of improving fundamentals and a valuation with room for expansion remains. He believes new deepwater project opportunities will emerge in 2018 and the funding backdrop for infrastructure spending has improved. Burleson reiterated his Buy rating and $30 price target on Aegion shares.
05/23/17
CHLM
05/23/17
UPGRADE
Target $25
CHLM
Buy
Aegion upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Eric Stine upgraded Aegion to Buy and raised his price target for the shares to $25 from $23. The recent pullback provides an attractive opportunity to own a "high-quality company" with positive trends across much of its business.
05/23/17
05/23/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Overweight from Neutral at JPMorgan with analyst Lisa Gill saying she believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted. 2. Aegion (AEGN) upgraded to Buy from Hold at Craig-Hallum with analyst Eric Stine saying the recent pullback provides an attractive opportunity to own a "high-quality company" with positive trends across much of its business. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Karen Holthouse saying there is upside to her $36 price target. Holthouse believes Wingstop is well positioned for digital ordering and off-premise tailwinds and expects an acceleration in same-store-sales driven by national advertising momentum. 4. Parexel (PRXL) upgraded to Neutral from Sell at Goldman Sachs with analyst Robert Jones citing reduced consensus expectations and industry consolidation. 5. On Deck Capital (ONDK) upgraded to Outperform from Market Perform at FBR Capital with analyst Bob Ramsey saying he believes the company's path to profitability creates "significant" upside for the shares over the next 12 months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/17
SIDC
08/02/17
DOWNGRADE
SIDC
Neutral
Aegion downgraded to Neutral from Buy at Sidoti
GRUB GrubHub
$55.82

-0.27 (-0.48%)

08/04/17
WEDB
08/04/17
NO CHANGE
WEDB
GrubHub deal kills bear thesis, says Wedbush
Wedbush analyst Aaron Turner says that GrubHub's (GRUB) deal with Yelp (YELP) renders the bear thesis on GrubHub "moot." The analyst explains that GrubHub's acquisition of Yelp's Eat 24 creates an entity that is so dominant that it will make competition in the space a non-factor for GrubHub. The analyst raised his price target on GrubHub to $55 from $50 and keeps an Outperform rating on the stock.
08/07/17
MSCO
08/07/17
UPGRADE
MSCO
Overweight
GrubHub upgraded to Overweight from Equal Weight at Morgan Stanley
08/07/17
08/07/17
UPGRADE
Target $59

Overweight
GrubHub upgraded to Overweight on earnings power at Morgan Stanley
As previously reported, Morgan Stanley upgraded GrubHub to Overweight from Equal Weight and raised its price target to $59 from $43. Analyst Brian Nowak said GrubHub is building a larger ecosystem with its 3 recently proposed acquisitions which will generate high incremental EBITDA, extend its size, and better enable the company to scale profitably and drive online delivery. Nowak is bullish on GrubHub's long-term earnings power and competitive position given its scale advantage and user base growth.
08/04/17
JMPS
08/04/17
NO CHANGE
JMPS
GrubHub outlook has improved, says JMP Securities
JMP Securities analyst Ronald Josey says that GrubHub's (GRUB) deals with Yelp (YELP) and Groupon (GRPN) can significantly accelerate the growth of online food ordering. The analyst recommends buying GrubHub's shares on further weakness as he thinks the deals can significantly boost its results. He increased his price target on the shares to $50 from $47and keeps an Outperform rating.
HIVE Aerohive
$3.35

-0.05 (-1.47%)

02/06/17
JMPS
02/06/17
DOWNGRADE
JMPS
Market Perform
Aerohive downgraded to Market Perform from Outperform at JMP Securities
05/04/17
WDLK
05/04/17
UPGRADE
Target $5
WDLK
Buy
Aerohive upgraded to Buy with $5 target at Wunderlich
Wunderlich analyst Matthew Robison upgraded Aerohive to Buy with a $5 price target following the company's Q1 results. The analyst views the stock as attractively valued given the company's progress.
05/04/17
WDLK
05/04/17
UPGRADE
WDLK
Buy
Aerohive upgraded to Buy from Hold at Wunderlich
02/06/17
JMPS
02/06/17
DOWNGRADE
JMPS
Market Perform
Aerohive downgraded on headwinds at JMP Securities
As noted earlier, JMP Securities downgraded Aerohive to Market Perform from Outperform. Analyst John Lucia says that the company's new pricing strategy indicates that it's facing increased competition and pricing pressure.
TCMD Tactile Systems
$32.97

-0.36 (-1.08%)

06/16/17
PIPR
06/16/17
NO CHANGE
Target $30
PIPR
Overweight
Piper tells investors to start positions in Tactile Systems
After analyzing the head and neck indication for Tactile Systems' Flexitouch system, Piper Jaffray analyst Matt O'Brien says investors should continue to start or add to positions in the name. The analyst is "quite bullish" on the impact of the head and neck indication. He believes the patient population is likely much more motivated to adopt given the quality of life impact. The market size is "significant" at over $1B domestically, O'Brien tells investors in a research note. He keeps an Overweight rating on Tactile Systems.
08/22/16
WBLR
08/22/16
INITIATION
WBLR
Outperform
Tactile Systems initiated with an Outperform at William Blair
William Blair analyst Margaret Kaczor initiated Tactile Systems with an Outperform rating.
08/08/17
ADAM
08/08/17
NO CHANGE
Target $37
ADAM
Buy
Tactile Systems price target raised to $37 from $28 at Canaccord
Canaccord analyst Jason Mills raised his price target on Tactile Systems to $37 from $28 following Q2 results. The company represents a solid, fundamentally sound growth company with strong results that reflect the experienced management team's ability to execute, said Mills, who reiterated his Buy rating on Tactile shares.
08/08/17
PIPR
08/08/17
NO CHANGE
Target $36
PIPR
Overweight
Tactile Systems price target raised to $36 from $30 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Tactile Systems Technology to $36 and "strongly" recommends purchase of the shares following the company's "strong" Q2 report. Tactile's key Flexitouch product grew 43% off a tough comparison despite introducing new products and a headwind from a insurance carrier contract change in the quarter, O'Brien tells investors in a post-earnings research note. He keeps an Overweight rating on the name.
AST Asterias
$3.30

-0.15 (-4.35%)

ANGO AngioDynamics
$16.40

-0.06 (-0.36%)

03/30/17
03/30/17
DOWNGRADE

Sector Weight
AngioDynamics downgraded to Sector Weight on valuation at KeyBanc
As previously reported, KeyBanc downgraded AngioDynamics to Sector Weight from Overweight. Analyst Matthew Misham said shares have reached his price target and he believes revenue growth is likely to remain challenged and it could take several years to improve the product portfolio.
03/30/17
CANT
03/30/17
NO CHANGE
Target $20
CANT
Overweight
AngioDynamics price target raised to $20 after earnings at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier raised his price target on AngioDynamics to $20 from $19 following the company's Q3 report, saying that while its revenues were lighter than expected as it emphasizes efficiency, he believes it is poised to accelerate revenue growth in addition to sustaining strong EPS growth and free cash flow. He keeps an Overweight rating on AngioDynamics shares.
03/31/17
CHLM
03/31/17
NO CHANGE
Target $20
CHLM
Buy
AngioDynamics turnaround thesis remains intact, says Craig-Hallum
Craig-Hallum analyst Charles Haff says that despite reporting revenue that was below his estimate, he believes the turnaround story at AngioDynamics remains intact, as profitability continues to trend in the right direction with EPS better than he expected. The analyst reiterates a Buy rating and $20 price target.
07/19/17
ADAM
07/19/17
NO CHANGE
Target $17
ADAM
Hold
AngioDynamics cash flow story improving, says Canaccord
Canaccord analyst Jason Mills said he views AngioDynamics as a strong and improving cash flow story that should be on investors' radar and recommends becoming more constructive on the stock below $15 a share. While the analyst does not expect top-line growth over the next year, he does expect improving gross margins and strong free cash flow and believes M&A could be a positive driver for the shares. Mills maintained his Hold rating and raised his price target to $17 from $16.50
CAMP CalAmp
$18.86

-0.12 (-0.63%)

10/31/16
MACQ
10/31/16
INITIATION
Target $14
MACQ
Neutral
CalAmp initiated with a Neutral at Macquarie
Macquarie analyst Andrew DeGasperi initiated CalAmp with a Neutral and a $14 price target.
04/19/17
CHLM
04/19/17
NO CHANGE
Target $19
CHLM
Buy
CalAmp record quarterly bookings set stage for growth, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss notes that CalAmp reported results and guidance in line with estimates as weakness seen in its North American MRM business the last several quarters is now behind them. The analyst believes CalAmp remains a great way to play the accelerating M2M, Internet of Things and connected car markets given its "strong portfolio" of both hardware and software solutions. He reiterates a Buy rating and $19 price target on the shares.
04/25/17
BNCH
04/25/17
INITIATION
Target $23
BNCH
Buy
CalAmp initiated with a Buy at Benchmark
Benchmark analyst Scott Searle initiated CalAmp with a Buy rating and $23 price target.
03/22/17
SIDC
03/22/17
DOWNGRADE
Target $18
SIDC
Neutral
CalAmp downgraded to Neutral from Buy at Sidoti
Sidoti downgraded CalAmp to Neutral from Buy with an $18 price target.
SCYX SCYNEXIS
$1.63

-0.01 (-0.61%)

05/09/17
NEED
05/09/17
DOWNGRADE
NEED
Hold
SCYNEXIS downgraded to Hold from Buy at Needham
05/09/17
05/09/17
DOWNGRADE

Hold
SCYNEXIS downgraded to Hold at Needham
As previously reported, Needham analyst Alan Carr downgraded SCYNEXIS to Hold from Buy after the company announced in a quarterly update that FDA has requested additional information to better understand IV SCY-078 risk for thrombosis. Although Scynexis may continue development of the oral formulation, the analyst believes FDA action around IV formulation is disruptive to overall SCY-078 strategy.
07/10/17
ROTH
07/10/17
INITIATION
Target $8.5
ROTH
Buy
SCYNEXIS initiated with a Buy at Roth Capital
Roth Capital analyst Michael Higgins started SCYNEXIS with a Buy rating and $8.50 price target.
07/10/17
07/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SeaSpine (SPNE) initiated with a Buy at H.C. Wainwright. 2. Puma Biotechnology (PBYI) resumed with an Outperform at Leerink. 3. SCYNEXIS (SCYX) initiated with a Buy at Roth Capital. 4. Tabula Rasa HealthCare (TRHC) initiated with a Buy at Chardan. 5. Matinas BioPharma (MTNB) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VIVO Meridian Bioscience
$13.60

0.05 (0.37%)

04/27/17
PIPR
04/27/17
NO CHANGE
PIPR
Underweight
Piper still sees competitive threats to Meridian, keeps at Underweight
Piper Jaffray analyst William Quirk noted that Meridian Bioscience reported better than expected Q2 revenue and earnings, with both Life Science and Diagnostics performance beating his forecast. However, he still sees increased risk of competition and thinks investor nervousness about dividend cuts will weigh on shares and keeps an Underweight rating on Meridian.
05/18/17
ADAM
05/18/17
NO CHANGE
Target $14
ADAM
Hold
Meridian Bioscience warning letter a setback, says Canaccord
Canaccord analyst Mark Massaro noted the FDA issued a warning letter to Meridian Bioscience regarding its Magellan Diagnostics subsidiary, which is 10%-12% of its revenue. The letter warned about the risk of inaccurate test results from certain lead poisoning tests. Massaro said it is difficult to determine what the impact will be on margins until it can resolve both the FDA and CDC concerns, but it is definitely a setback for the company. Massaro maintained his Hold rating and lowered his price target to $14 from $15 on Meridian Bioscience shares.
05/17/17
PIPR
05/17/17
NO CHANGE
PIPR
Underweight
Piper sees 'reputational damage' for Meridian after FDA warning
Piper Jaffray analyst William Quirk expects "reputational damage" to Meridian Bioscience after the FDA issued a warning statement against using the company's Magellan LeadCare test systems citing the possibility of false negatives. It is possible Magellan revenue could fall by as much as 50% as physicians unplug systems, Quirk tells investors in a research note. He keeps an Underweight rating on shares of Meridian.
04/27/17
RAJA
04/27/17
NO CHANGE
RAJA
Underperform
Raymond James 'struggles' with Meridian Bioscience's valuation
Raymond James analyst Nicholas Jansen reiterated his Underperform rating following the Q2 report that beat low expectations. Jansen continues to believe the portfolio of assets will struggle to grow and said sustainability is a big question mark, keeping him cautious as he "struggles" with valuation.
EXAC Exactech

QTNA Quantenna Communications
$17.88

-0.13 (-0.72%)

11/22/16
MSCO
11/22/16
INITIATION
Target $24
MSCO
Overweight
Quantenna Communications initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Joseph Moore initiated Quantenna Communications with an Overweight and a $24 price target.
04/04/17
BNCH
04/04/17
INITIATION
Target $28
BNCH
Buy
Quantenna Communications initiated with a Buy at Benchmark
Benchmark analyst Gary Mobley started Quantenna Communications with a Buy rating and $28 price target.
12/05/16
NEED
12/05/16
UPGRADE
NEED
Strong Buy
Quantenna Communications upgraded to Strong Buy from Buy at Needham
Needham analyst Quinn Bolton upgraded Quantenna Communications to Strong Buy with a $25 price target saying the pullback in shares has created a buying opportunity.
11/22/16
ROTH
11/22/16
INITIATION
Target $25
ROTH
Buy
Quantenna Communications initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva started Quantenna Communications with a Buy rating and $25 price target as he believes it represents a differentiated investment opportunity in wireless connectivity infrastructure semiconductors.
VRML Vermillion
$1.38

-0.08 (-5.48%)

11/09/16
11/09/16
NO CHANGE

Vermillion's OVA1 technology receives Level B recommendation
Vermillion company Aspira Labs announced the inclusion of the OVA1 /"Multivariate Index Assay" in The American College of Obstetricians and Gynecologists Practice Bulletin Number 174, dated November 2016. Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. The new guidelines now recommend that all obstetricians and gynecologists, in evaluating women with adnexal masses when the mass does not fulfill Level A criteria of a low risk transvaginal ultrasound, should use risk assessment tools such as OVA1 as listed in the bulletin. Based on this, OVA1 is the only recommended Level B tool with FDA clearance for use in assessing ovarian cancer risk in adnexal masses.
RVLT Revolution Lighting
$7.30

-0.03 (-0.41%)

11/10/16
ROTH
11/10/16
NO CHANGE
Target $12
ROTH
Buy
Revolution Lighting price target lowered to $12 from $19 at Roth Capital
Roth Capital analyst Craig Irwin lowered his price target for Revolution Lighting to $12 from $19 after the company reported weak Q3 results. The analyst expects Q4 and 2017 growth to benefit from broadening distribution with a new channel partner initiative and cross selling of TNT Energy's capabilities. The analyst reiterates a Buy rating on the shares.
BSQR Bsquare Corp
$5.05

-0.25 (-4.72%)

PTN Palatin
$0.40

-0.0226 (-5.41%)

11/02/16
ROTH
11/02/16
NO CHANGE
Target $7
ROTH
Buy
Palatin price target raised to $7 from $4 at Roth Capital
01/10/17
LEER
01/10/17
DOWNGRADE
Target $25
LEER
Market Perform
AMAG Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Leerink analyst Joseph Schwartz downgraded AMAG Pharmaceuticals (AMAG) to Market Perform from Outperform after the company provided a "disappointing update" related to the Makena auto-injector program. Furthermore, the analyst notes that the licensing agreement with Palatin (PTN) for its hypoactive sexual desire disorder drug Rekynda could drive incremental value but will require "sizable upfront investment" and have to clear regulatory and commercialization hurdles before that takes place. Nonetheless, Schwartz notes that AMAG's preliminary Q4 results and FY17 financial estimates were in-line with his bullish outlook for 2016-2017. He also lowered his price target on AMAG's shares to $25 from $39.
EXA Exa Corp.
$13.75

-0.21 (-1.50%)

12/22/16
NEED
12/22/16
INITIATION
Target $18
NEED
Buy
Exa Corp. assumed with a Buy at Needham
Needham analyst Richard Valera assumed coverage on Exa Corp. with a Buy and an $18 price target.
02/28/17
BARD
02/28/17
INITIATION
Target $18
BARD
Outperform
Exa Corp. assumed with an Outperform at Baird
Baird analyst Rob Oliver assumed coverage on Exa Corp. with an Outperform and $18 price target.
03/17/17
ADAM
03/17/17
DOWNGRADE
Target $15
ADAM
Hold
Exa Corp. downgraded to Hold from Buy at Canaccord
Canaccord Genuity analyst David Hynes downgraded Exa Corp. to Hold saying management has had a "rapid reversal in tone" from an upbeat analyst day only 90 days ago. The analyst expects the company's 2018 growth to fall in the mid-single digits and feels any plans for continued margin expansion is pushed out by at least a year. He cut his price target for the shares to $15 from $18.
08/30/16
ADAM
08/30/16
NO CHANGE
Target $18
ADAM
Buy
Exa Corp. results may stall advance, buy thesis intact, says Canaccord
Canaccord analyst David Hynes noted Exa Corp. reported mixed Q2 results, including a revenue shortfall which he believes could stall the stock's advance. The analyst said his buy thesis remains intact and he believes the company can be the kind of off-the-radar small cap stock that delivers outsized returns. Hynes said the mix toward subscription and licenses is favorable and sees margin expansion and unchanged guidance as favorable. Hynes reiterated his Buy rating and raised his price target to $18 from $15 on Exa Corp. shares.

TODAY'S FREE FLY STORIES

MDT

Medtronic

$83.52

0.11 (0.13%)

, COTY

Coty

$19.55

0.32 (1.66%)

20:25
08/21/17
08/21
20:25
08/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$83.52

0.11 (0.13%)

COTY

Coty

$19.55

0.32 (1.66%)

TOL

Toll Brothers

$38.26

0.11 (0.29%)

DSW

DSW

$15.69

-0.15 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 06

    Sep

  • 20

    Sep

ENR

Energizer

$41.24

-0.09 (-0.22%)

18:58
08/21/17
08/21
18:58
08/21/17
18:58
Hot Stocks
Energizer CEO acquires 12,112 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOMB

Home Bancshares

$23.51

0.11 (0.47%)

, SGBK

Stonegate Bank

$46.70

0.34 (0.73%)

18:41
08/21/17
08/21
18:41
08/21/17
18:41
Hot Stocks
Home Bancshares receives regulatory approvals for merger with Stonegate Bank »

Home BancShares (HOMB)…

HOMB

Home Bancshares

$23.51

0.11 (0.47%)

SGBK

Stonegate Bank

$46.70

0.34 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

ADP

ADP

$102.89

-1.52 (-1.46%)

18:32
08/21/17
08/21
18:32
08/21/17
18:32
Periodicals
ADP CEO: Ackman refused to meet because he needed 'leverage,' CNBC says »

After ADP said its board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

TWX

Time Warner

$102.11

0.92 (0.91%)

, SNAP

Snap

$13.58

-0.43 (-3.07%)

18:18
08/21/17
08/21
18:18
08/21/17
18:18
Periodicals
CNN begins streaming daily news show on Snapchat, Reuters reports »

CNN, which is owned by…

TWX

Time Warner

$102.11

0.92 (0.91%)

SNAP

Snap

$13.58

-0.43 (-3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 24

    Aug

  • 13

    Sep

KKR

KKR

18:11
08/21/17
08/21
18:11
08/21/17
18:11
Hot Stocks
Breaking Hot Stocks news story on KKR »

ValueAct raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$34.60

0.62 (1.82%)

18:05
08/21/17
08/21
18:05
08/21/17
18:05
Hot Stocks
Baozun reports Q2 Total Gross Merchandise Volume RMB3.604B »

An increase of 63.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BZUN

Baozun

$34.60

0.62 (1.82%)

18:03
08/21/17
08/21
18:03
08/21/17
18:03
Earnings
Baozun sees Q3 revenue RMB870M-RMB910M »

The company will begin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BZUN

Baozun

$34.60

0.62 (1.82%)

18:02
08/21/17
08/21
18:02
08/21/17
18:02
Earnings
Breaking Earnings news story on Baozun »

Baozun reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BZUN

Baozun

$34.60

0.62 (1.82%)

18:01
08/21/17
08/21
18:01
08/21/17
18:01
Earnings
Baozun reports Q2 EPS 8c, consensus 10c »

Reports Q2 revenue $131M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

KKR

KKR

18:00
08/21/17
08/21
18:00
08/21/17
18:00
Periodicals
KKR near 'clinching' $3B commitment from NYC pension system, Bloomberg says »

KKR is getting close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESV

Ensco

$4.19

-0.09 (-2.10%)

, NBL

Noble Energy

$23.54

-0.11 (-0.47%)

17:56
08/21/17
08/21
17:56
08/21/17
17:56
Hot Stocks
Ensco awarded contract by Noble Energy »

Ensco (ESV) announced…

ESV

Ensco

$4.19

-0.09 (-2.10%)

NBL

Noble Energy

$23.54

-0.11 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 05

    Oct

GDOT

Green Dot

$46.58

0.31 (0.67%)

17:51
08/21/17
08/21
17:51
08/21/17
17:51
Hot Stocks
Breaking Hot Stocks news story on Green Dot »

Harvest Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RT

Ruby Tuesday

$1.84

-0.06 (-3.16%)

, RIG

Transocean

$7.32

-0.16 (-2.14%)

17:46
08/21/17
08/21
17:46
08/21/17
17:46
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ruby…

RT

Ruby Tuesday

$1.84

-0.06 (-3.16%)

RIG

Transocean

$7.32

-0.16 (-2.14%)

NDSN

Nordson

$125.12

0.99 (0.80%)

FN

Fabrinet

$39.82

-0.26 (-0.65%)

TEDU

Tarena

$18.61

0.59 (3.27%)

ZAYO

Zayo Group

$32.97

-0.08 (-0.24%)

PINC

Premier

$32.78

-0.16 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 29

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Dec

RIG

Transocean

$7.32

-0.16 (-2.14%)

17:41
08/21/17
08/21
17:41
08/21/17
17:41
Hot Stocks
Transocean director acquires 2,000 registered shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

RDN

Radian Group

$16.46

-0.26 (-1.56%)

17:38
08/21/17
08/21
17:38
08/21/17
17:38
Hot Stocks
Radian Group CEO Thornberry buys 15,000 shares »

Radian Group CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RT

Ruby Tuesday

$1.84

-0.06 (-3.16%)

17:38
08/21/17
08/21
17:38
08/21/17
17:38
Earnings
Ruby Tuesday reports Q4 adjusted EPS 6c vs 10c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 06

    Dec

SRNE

Sorrento Therapeutics

$1.70

-0.05 (-2.86%)

17:29
08/21/17
08/21
17:29
08/21/17
17:29
Hot Stocks
Sorrento closes transactions contemplated by contribution pact with Celularity »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

GPN

Global Payments

$94.57

0.81 (0.86%)

17:24
08/21/17
08/21
17:24
08/21/17
17:24
Hot Stocks
Global Payments Chairman William Jacobs sells 8,428 shares of company stock »

Global Payments Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$267.70

0.09 (0.03%)

17:19
08/21/17
08/21
17:19
08/21/17
17:19
Hot Stocks
Northrop Grumman awarded $328.6M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

BA

Boeing

$235.68

-0.09 (-0.04%)

17:18
08/21/17
08/21
17:18
08/21/17
17:18
Hot Stocks
Boeing awarded $349.2M government contract »

The Boeing Co.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$301.88

2.68 (0.90%)

17:17
08/21/17
08/21
17:17
08/21/17
17:17
Hot Stocks
Lockheed Martin awarded $427M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

PBFX

PBF Logistics

$20.80

-0.05 (-0.24%)

17:11
08/21/17
08/21
17:11
08/21/17
17:11
Hot Stocks
Breaking Hot Stocks news story on PBF Logistics »

Carlos Slim reports 5.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$48.14

0.45 (0.94%)

17:10
08/21/17
08/21
17:10
08/21/17
17:10
Periodicals
Yahoo owes $5.5M to SCA Promotions after backing out of contract, Reuters says »

The 5th U.S. Circuit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 31

    Aug

  • 06

    Sep

  • 19

    Sep

XOM

Exxon Mobil

$76.38

-0.26 (-0.34%)

17:07
08/21/17
08/21
17:07
08/21/17
17:07
Hot Stocks
Exxon Mobil says fire at a refinery in Botlek, Rotterdam 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.